1. Home
  2. PCYO vs LUNG Comparison

PCYO vs LUNG Comparison

Compare PCYO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

HOLD

Current Price

$11.49

Market Cap

267.7M

Sector

Utilities

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.51

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCYO
LUNG
Founded
1976
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Industrial Specialties
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.7M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PCYO
LUNG
Price
$11.49
$2.51
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
46.6K
1.1M
Earning Date
01-07-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
12.50
N/A
EPS
0.54
N/A
Revenue
$26,087,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$20.98
N/A
Revenue Growth
N/A
15.59
52 Week Low
$9.65
$1.31
52 Week High
$12.99
$9.37

Technical Indicators

Market Signals
Indicator
PCYO
LUNG
Relative Strength Index (RSI) 47.93 69.75
Support Level $11.39 $2.43
Resistance Level $11.80 $2.65
Average True Range (ATR) 0.35 0.21
MACD -0.03 0.05
Stochastic Oscillator 16.75 92.13

Price Performance

Historical Comparison
PCYO
LUNG

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: